Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -560.85% is 541% below its 5-year average of -87.56%, near the high end of its 5-year range (-3004.51%–55.20%).
19.07% above its 12-month average of -693.01%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -483.91%.
NET PROFIT MARGIN
-560.85%
NET PROFIT MARGIN AVG TTM
-693.01%
NET PROFIT MARGIN AVG 3Y
-239.38%
NET PROFIT MARGIN AVG 5Y
-87.56%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+19.07%
CURRENT VS 3Y AVG
-134.29%
CURRENT VS 5Y AVG
-540.51%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 789 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Monte Rosa Therapeutics, Inc.
Market Cap
$839.73M
Net Profit Margin
-560.85%
TTM Avg
-693.01%
3Y Avg
-239.38%
5Y Avg
-87.56%
Market Cap
$840.18M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$835.64M
Net Profit Margin
-5933.45%
TTM Avg
-505.88%
3Y Avg
-252.94%
5Y Avg
-252.94%
Market Cap
$833.62M
Net Profit Margin
-61.32%
TTM Avg
-78.55%
3Y Avg
-9174.62%
5Y Avg
-9174.62%
Market Cap
$830.86M
Net Profit Margin
-82.49%
TTM Avg
-271.33%
3Y Avg
-235.13%
5Y Avg
-173.69%
Market Cap
$857.24M
Net Profit Margin
-39.20%
TTM Avg
-57.59%
3Y Avg
-24.68%
5Y Avg
-1.42%
Market Cap
$861.70M
Net Profit Margin
-6.85%
TTM Avg
-13.95%
3Y Avg
-29.17%
5Y Avg
-39.83%
Market Cap
$863.01M
Net Profit Margin
-173.85%
TTM Avg
-104.63%
3Y Avg
-54.62%
5Y Avg
-54.62%
Market Cap
$863.49M
Net Profit Margin
116.30%
TTM Avg
67.23%
3Y Avg
16.07%
5Y Avg
4.15%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | $839.73M | -560.85% | -693.01% | -239.38% | -87.56% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $840.18M | 0.00% | 0.00% | 0.00% | 0.00% |
| Alumis Inc. (ALMS)vs › | $835.64M | -5933.45% | -505.88% | -252.94% | -252.94% |
| Beta Bionics, Inc. (BBNX)vs › | $833.62M | -61.32% | -78.55% | -9174.62% | -9174.62% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $830.86M | -82.49% | -271.33% | -235.13% | -173.69% |
| QuidelOrtho Corporation (QDEL)vs › | $857.24M | -39.20% | -57.59% | -24.68% | -1.42% |
| SI-BONE, Inc. (SIBN)vs › | $861.70M | -6.85% | -13.95% | -29.17% | -39.83% |
| SL Science Holding Ltd (SLBT)vs › | $863.01M | -173.85% | -104.63% | -54.62% | -54.62% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $863.49M | 116.30% | 67.23% | 16.07% | 4.15% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $868.65M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-43.8%
Net Profit Margin
-560.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -483.91% |
| 2026-03-31 | -1057.08% |
| 2025-12-31 | -1658.94% |
| 2025-09-30 | -212.10% |
| 2025-06-30 | -53.01% |
| 2025-03-31 | 55.20% |
| 2024-12-31 | 22.16% |
| 2024-09-30 | -258.89% |
| 2024-06-30 | -645.58% |
| 2024-03-31 | -3004.51% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
